Raymond James Thinks Haemonetics Growth Is ‘Underappreciated’
Earlier this week, Raymond James attended Haemonetics Corp’s (NYSE:HAE) Investor Day, where the management team presented a new Long-Range Plan (LRP), including…
5 Risks For Lululemon
Lululemon Athletica inc’s (NASDAQ: LULU) comps are likely to slow going ahead, Goldman Sachs’ Lindsay Drucker Mann said in a report. She maintained a Sell rating on the company, while reducing the price target from $48 to $46.